Litton BIONETICS

5516 Nicholson Lane, Kensington, Maryland 20795 (301) 881-5400

February 16, 1976

Paul L. Wright, Ph.D.
Manager, Toxicology
Monsanto Company
800 North Lindbergh Boulevard
St. Louis, Missouri 63166

REFERENCE: LBI Proposal No. 1389

Dear Dr. Wright:

Litton Bionetics, Inc. (LBI) is pleased to submit our proposal to evaluate the effects of low levels of a polychlorinated biphenyl mixture on nonhuman primates. LBI can provide the personnel, facilities, an ongoing rhesus monkey (Macaca mulatta) breeding colony, and over 13 years of nonhuman primate breeding and husbandry experience to provide a capability to perform this work for the Monsanto Company which can be matched by few, if any, other laboratories in the world.

Our experience in this area includes the management of numerous breeding colonies which have involved the production of up to 600 neonates comprising 11 species yearly. LBI currently produces approximately 400 rhesus monkey pregnancies annually, 200 of which are for commercial customers. Our especially-designed nonhuman breeding areas are light and temperature controlled and, like all of our Kensington, Maryland, and Falls Church, Virginia, animal facilities are American Association for Accreditation of Laboratory Animal Care-certified. Our staff of veterinarians, veterinary pathologists, technicians, and animal care personnel trained in the area of primate maintenance and breeding are available for assignment to the program immediately upon award. Of equal importance is the fact that rhesus monkeys from our commercial colony with known reproductive histories are available for immediate use on this program. This assures the Monsanto Company of a timely start to the program without the delays associated with primate acquisition (possibly requiring months in today's climate of nonhuman primate shortages) and quarantine. LBI's complete biomedical capability includes a modern clinical testing laboratory which will perform all the required testing in the same building complex as the animals are housed.

Dr. David P. Martin, V.M.D., Director of the Department of Laboratory Animal Medicine and Science, and a diplomate of the American College of Laboratory Animal Medicine, will oversee the primate reproduction portion of the program, while Robert P. Beliles, Ph.D., who brings to this program

over ten years of experience in reproduction and toxicology studies,will evaluate and report on any toxicological aspects of the program.

We trust that you will view our proposal as a step towards what we hope will be a continuing dialogue with the Monsanto Company regarding the most efficient and cost-effective way to complete a study which will give you the maximum amount of information in the important area of chronic ingestion of low levels of polychlorinated biphenyl mixtures. To this end, our enclosed proposal clearly spells out what has been included in the way of clinical testing, animal maintenance, and necropsy procedures. Specifically, you will note that we have included a basic clinical testing package, part of which is to be performed on the SMA 1260^{R} machine. By utilizing the SMA 1260^{R}, we can supply a large proportion of the needed tests at a greatly reduced cost even though certain other tests, not necessarily associated with this study, are also included. An expanded clinical testing program, with a view towards evaluating other possible effects, has been presented for your consideration. These optional clinical tests should be the subject of further discussions. Likewise, the exact timing of the euthanasia of the test animals and the disposition of offspring born to experimental females should be discussed, although we have designed our proposal with one alternative clearly stated.

This study could be initiated immediately after authorization and receipt of the compound. The fixed price to perform the basic study is $138,500. If additional clinical testing is desired the price would of course have to be adjusted according to the amount of additional testing desired.

You are invited to visit our facility and talk with our staff regarding the various aspects of the program, and we look forward to being able to conduct this study for you. If questions should arise regarding the scientific or technical areas of this program, please do not hesitate to contact Dr. David P. Martin, at (301) 881-5600.

Sincerely,

R. V. Borghese

Richard V. Borghese
Vice President
Contracts and Finance

RVB:af
Enclosures